

## Accepted Manuscript

Title: Anti-Phospholipid Syndrome: Current Opinion on Mechanisms involved, Laboratory Characterization and Diagnostic Aspects

Author: Jean Amiral Marie Peyrafitte Claire Dunois Anne Marie Vissac Jerard Seghatchian



PII: S1473-0502(17)30142-8  
DOI: <http://dx.doi.org/doi:10.1016/j.transci.2017.07.014>  
Reference: TRASCI 2207

To appear in:

Please cite this article as: Amiral J, Peyrafitte M, Dunois C, Vissac AM, Seghatchian J, Anti-Phospholipid Syndrome: Current Opinion on Mechanisms involved, Laboratory Characterization and Diagnostic Aspects. *Transfusion and Apheresis Science* (2017), <http://dx.doi.org/10.1016/j.transci.2017.07.014>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Anti-Phospholipid Syndrome: Current Opinion on Mechanisms involved, Laboratory Characterization and Diagnostic Aspects

**Jean Amiral**, SH-Consulting, Andrésy (France) and Scientific and Technical Advisor for Hyphen BioMed, Sysmex group, Neuville sur Oise (France)

**Marie Peyrafitte**, Validation manager, HYPHEN BioMed, Neuville-sur-Oise (France)

**Claire Dunois**, Clinical studies director, HYPHEN BioMed, Neuville-sur-Oise (France)

**Anne Marie VISSAC**, Technical director, HYPHEN BioMed, Neuville-sur-Oise (France)

**Jerard Seghatchian**, International Consultancy in Blood Components Quality/Safety Improvement, Audit/ Inspection and DDR Strategies, London, (UK)

**E-mails for correspondence:**

[jamiral@hyphen-biomed.com](mailto:jamiral@hyphen-biomed.com)

[jseghatchian@btopenworld.com](mailto:jseghatchian@btopenworld.com)

**Key words:**

Anti-Phospholipid syndrome; phospholipid dependent antibodies;  $\beta$ 2-Glycoprotein 1; prothrombin; thrombosis; clotting assays; immunoassays.

**Abstract:**

Anti-phospholipid syndrome is a complex and severe clinical situation, associated with symptoms such as recurrent thrombosis, arterial or venous, at any site, pregnancy loss, and other related syndromes. These clinical burdens, are highly variable from patient to patient, and are associated with biological abnormalities, such as the presence of the Lupus Anticoagulant or Phospholipid dependent antibodies, confirmed on two occasions at least 12 weeks apart. From the diagnosis standpoint, both, functional (clotting) or immunological assays, are difficult to

Download English Version:

<https://daneshyari.com/en/article/5664554>

Download Persian Version:

<https://daneshyari.com/article/5664554>

[Daneshyari.com](https://daneshyari.com)